A phase 1 trial of low-dose decitabine in NHL and CLL reported dose-limiting myelosuppression.297 Decitabine combined with R-CHOP is being studied in a phase 1/2 trial (NCT02951728) of untreated DLBCL patients with International Prognostic Index (IPI) >1. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.